NEW YORK, NY / ACCESSWIRE / October 23, 2018 / Major U.S. equities finished lower Monday on a combination of rising interest rates and global growth concerns. Investors await a flood of corporate earnings this week as over 150 companies are scheduled to release earnings. The Dow Jones Industrial Average dropped 0.5 percent to close at 25,317.41, while the S&P 500 Index declined 0.43 percent to close at 2,755.88. The Nasdaq Composite Index gained 0.26 percent to close at 7,468.63.
"You need the market to calm down for investors to jump back in," according to Jeremy Klein, the chief market strategist at FBN Securities. "Hopefully, earnings will help with that," Klein added.
RDI Initiates Coverage on:
Endo International plc
AbbVie's stock moved 4.21% lower Monday, to close the day at $84.27. The stock recorded a trading volume of 7,621,062 shares, which was above its three months average volume of 5,341,420 shares. In the last year, AbbVie's shares have traded in a range of 83.50 - 125.86. The share price has gained 0.92% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $93.31 is below its 200-day moving average of $95.96. Shares of the company are trading at a Price to Earnings ratio of 20.92. Shares of AbbVie have fallen roughly 8.66 percent in the past month and are down 12.86 percent year-to-date.
Access RDI's AbbVie Inc. Research Report at:
On Monday, shares of Endo International recorded a trading volume of 2,839,290 shares, which was below the three months average volume of 4,590,881 shares. The stock ended the day 3.02% higher at $18.06. The share price has fallen 2.38% from its 52
Access RDI's Endo International plc Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.